0
0
0
1001
Since January 2020, the value of Moderna’s stock—which had embarked on a steady decline since its IPO—grew from $18.89 per share to its current value of $339.57 per share, thanks to the success of its COVID-19 vaccine.
When the genetic sequence of SARS-CoV-2 was published on January 11, NIH scientists and Moderna...